Search
Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week on its first-in-class orexin agonist for treating narcolepsy type 1
Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two...
Sep 12
Elias Zerhouni and Andy Plump discuss the future of multispecific biologics
Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind...
Apr 7
From Japan, Takeda's CEO Christophe Weber talks about the company's Japanese roots, but global transformation - plus, five key pipeline assets
He describes Takeda's HQ and R&D facilities in Japan, but also how global markets have grown to dominate the company's business since he...
Nov 18, 2024
Christophe Weber describes Takeda's global perspective on R&D and business development
Takeda's CEO talks about the $4B+ Nimbus acquisition, recent approvals, and what's ahead for the company in 2024.
Jan 8, 2024
.png){kind=logo}
